Benzo[h]quinazolin-4-amine and thieno[3,2-h]quinazolin-4-amine derivatives for the treatment of cancer

A compound of formula (IB)

• or a pharmaceutically acceptable salt thereof;
• wherein A is selected from group (A1) and group (A2):
• wherein #1 is attached to the carbon atom forming the oxime moiety and wherein group (A1) is optionally substituted by one or two R10 and group (A2) is optionally substituted by one R10;
• each R10 is independently halogen or —NH2;
• X is —O—, —C(═O)—, —C(═CH2)—, —CH2—, —NH— or —N(C1-C4alkyl)- and wherein X is a bond when R2 is halogen or —CN and wherein when X is —C(═O)—R2 is not hydrogen;
• or X—R2 is hydrogen;
• Ra and Rb are both methyl, or together form a —CH2—CH2—CH2— or a —CH2—CH2—CH2—CH2-bridging moiety;
• R1 is —Y—R3;
• Y is a bond or C1-C6alkylene wherein one non-terminal —CH2-moiety may be replaced by —O—;
• R3 is hydrogen, —CN, —OH, C1-C4haloalkyl, C2-C4alkenylene-R4, C2-C4alkynylene-R4, —O-C1-C4alkylene-R4, —O-C1-C4haloalkyl, —NH2, —NH(C1-C4alkylene-R4), —N(C1-C4alkylene-R4)2, —C(═O)—OH, —C(═O)—O—C1-C4alkylene-R4, —C(═O)—NH2, —C(═O)—NH(C1-C4alkylene-R4), —C(═O)—N(C1-C4alkylene-R4)2, Cycle P, Cycle Q, —O-Cycle P, —O-Cycle Q or —S(O2)-C1-C4alkyl;
• R4 is hydrogen, —NH2, —NH(C1-C2alkyl) or —N(C1-C2alkyl)2;
• Cycle P is a 5-6-membered saturated or partially unsaturated carbocyclic ring optionally substituted by one to three R5 or is a 5-6-membered saturated or partially unsaturated heterocyclic ring containing one to two heteroatoms selected from N and O optionally substituted by one to three R5;
• each R5 is independently —NH2, —OH, —CN, C1-C4alkyl, C1-C4alkylene-R11, —O-C1-C2alkyl or oxo;
• each R11 is independently halogen, —NH2, —OH, —CN or —O-C1-C2alkyl;
• Cycle Q is phenyl optionally substituted by one to three R6, or is a 5-6-membered heteroaryl containing one to two heteroatoms selected from N, S and O optionally substituted by one to three R6;
• each R6 is independently —NH2, —OH, —CN, C1-C2alkyl or —O-C1-C2alkyl;
• R2 is hydrogen, halogen, —CN, C1-C4alkyl optionally substituted by one or two R7, or is a 4- to 7-membered saturated carbocyclic ring optionally substituted by one or two R8, or is a 4- to 7-membered saturated heterocyclic ring containing one-N(R9)-moiety as ring member and otherwise containing only carbon atoms as ring members;
• each R7 is independently —OH, halogen, —NH2, —NH(C1-C2alkyl), —N(C1-C2alkyl)2 or —NH(—C(═O)—C1-C2alkyl);
• each R8 is independently —OH, halogen, —NH2, —NH(C1-C2alkyl), —N(C1-C2alkyl)2, —NH(—C(═O)—C1-C2alkyl) or C1-C2alkyl;
• and
• R9 is hydrogen, C1-C4alkyl or —C(═O)—C1-C2alkyl.